Cns Pharmaceuticals, INC 10-Q quarterly reports

CNS Pharmaceuticals, Inc. filed its Q2 2026 Form 10-Q, detailing financial performance, operational updates, and strategic shifts, including a pivot from glioblastoma multiforme and exploration of out-licensing legacy assets.

CNS Pharmaceuticals reported a net loss of $4.94 million for Q1 2026, an increase from the prior year, alongside a strategic shift towards new therapies and out-licensing legacy assets.

CNS Pharmaceuticals reported a reduced net loss and increased cash, but its Berubicin trial failed to meet its primary endpoint, shifting focus to TPI 287 development.

CNS Pharmaceuticals reported an increased net loss for the first half of 2025 and revealed its Berubicin trial did not meet its primary overall survival endpoint, despite successful capital raises.

CNS Pharmaceuticals' Q1 2025 results show increased R&D spending and a net loss, with the company evaluating paths forward for Berubicin and focusing on TPI 287 development.

CNS Pharmaceuticals reported a net loss of $11.7 million for the nine months ended September 30, 2024, while continuing to advance its clinical trial for Berubicin and securing new licensing agreements.

CNS Pharmaceuticals reported its second quarter 2024 financial results, highlighting ongoing clinical trial progress and recent capital raising activities.

CNS Pharmaceuticals reported a net loss of $3.54 million for the first quarter of 2024, while also navigating ongoing Nasdaq listing compliance issues.